Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Oscar D. Pons-Belda"'
Publikováno v:
Diagnostics, Vol 12, Iss 5, p 1244 (2022)
We recently published some concerns with new technologies which are based on circulating tumor DNA (ctDNA) for early cancer detection. Most of our published criticism, including a commentary in this journal, has focused on tests developed by the biot
Externí odkaz:
https://doaj.org/article/bec9f5adf5f94b468f0d17ed4aaed3f4
Publikováno v:
Diagnostics, Vol 11, Iss 12, p 2171 (2021)
Circulating tumor DNA (ctDNA) is a new pan-cancer tumor marker with important applications for patient prognosis, monitoring progression, and assessing the success of the therapeutic response. Another important goal is an early cancer diagnosis. Ther
Externí odkaz:
https://doaj.org/article/a0c7780c31f1490b965aed156d06f4d7
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 31:1146-1150
Cancer screening has been a major research front for decades. The classical circulating biomarkers for cancer (such as PSA, CEA, CA125, AFP, etc.) are neither sensitive nor specific and are not recommended for population screening. Recently, circulat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::528b1e096490f0513874f37bd6f668e0
https://doi.org/10.1158/1055-9965.epi-22-0102
https://doi.org/10.1158/1055-9965.epi-22-0102
Autor:
Annie Ren, Dorsa Sohaei, Antigona Ulndreaj, Oscar D. Pons-Belda, Amaia Fernandez-Uriarte, Ioannis Zacharioudakis, George B. Sigal, Martin Stengelin, Anu Mathew, Christopher Campbell, Nikhil Padmanabhan, Daniel Romero, Jessica Joe, Antoninus Soosaipillai, Vathany Kulasingam, Tony Mazzulli, Xinliu A. Li, Allison McGeer, Eleftherios P. Diamandis, Ioannis Prassas
Publikováno v:
Clinical Chemistry and Laboratory Medicine (CCLM). 60:771-777
Objectives Widespread SARS-CoV-2 testing is invaluable for identifying asymptomatic/pre-symptomatic individuals. There remains a technological gap for highly reliable, easy, and quick SARS-CoV-2 diagnostic tests suitable for frequent mass testing. Co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3641d0ef506acdfed416ab2f025b0964
https://doi.org/10.1515/cclm-2021-1142
https://doi.org/10.1515/cclm-2021-1142
Autor:
Antigona Ulndreaj, Dorsa Sohaei, Simon Thebault, Oscar D. Pons-Belda, Amaia Fernandez-Uriarte, Christopher Campbell, David Cheo, Martin Stengelin, George Sigal, Mark S. Freedman, Isobel A. Scarisbrick, Ioannis Prassas, Eleftherios P. Diamandis
Publikováno v:
Diagnosis.
Objectives Neurofilament light (NfL) chain is a marker of neuroaxonal damage in various neurological diseases. Here we quantitated NfL levels in the cerebrospinal fluid (CSF) and serum from patients with multiple sclerosis (MS) and controls, using th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d37587aa49777bb1e398428d84f71f5
https://doi.org/10.1515/dx-2022-0125
https://doi.org/10.1515/dx-2022-0125
Publikováno v:
EJIFCC. 33(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8cbf90b2a60acf97b462eba3162e8e5d
https://pubmed.ncbi.nlm.nih.gov/36447802
https://pubmed.ncbi.nlm.nih.gov/36447802
Autor:
Oscar D. Pons-Belda, Mª Agustina Alonso-Álvarez, Juan David González-Rodríguez, Laura Mantecón-Fernández, Fernando Santos-Rodríguez
Publikováno v:
International Journal of Molecular Sciences. 24:6661
Fibroblast growth factor 23 (FGF23) was identified at the turn of the century as the long-sought circulating phosphatonin in human pathology. Since then, several clinical and experimental studies have investigated the metabolism of FGF23 and revealed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa3382dbc8ffc03be0e5309a0416ab7f
https://doi.org/10.3390/ijms24076661
https://doi.org/10.3390/ijms24076661
Autor:
Antigona Ulndreaj, Davor Brinc, Mehmet Altan, Oscar D. Pons-Belda, Amaia Fernandez-Uriarte, Hong Mu-Mosley, Farjana Fattah, Mitchell S. von Itzstein, Antoninus Soosaipillai, Vathany Kulasingam, Nicolas L. Palaskas, David E. Gerber, Eleftherios P. Diamandis, John V. Heymach, Ioannis Prassas
Publikováno v:
Clinical chemistry and laboratory medicineReferences. 61(1)
Objectives Immune checkpoint inhibitors (ICIs) cause a variety of toxicities, including immune-related adverse events (irAEs), but there are no biomarkers to predict their development. Guidelines recommend measuring circulating cardiac troponin I (cT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e039e020a6d2399e39dfa8342caa72a
https://pubmed.ncbi.nlm.nih.gov/36287134
https://pubmed.ncbi.nlm.nih.gov/36287134
Publikováno v:
Diagnostics
Diagnostics, Vol 11, Iss 2171, p 2171 (2021)
Diagnostics, Vol 11, Iss 2171, p 2171 (2021)
Circulating tumor DNA (ctDNA) is a new pan-cancer tumor marker with important applications for patient prognosis, monitoring progression, and assessing the success of the therapeutic response. Another important goal is an early cancer diagnosis. Ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c52125e27194b2a1db8d7c685ddd3a88
https://pubmed.ncbi.nlm.nih.gov/34943407
https://pubmed.ncbi.nlm.nih.gov/34943407
Publikováno v:
Clinical chemistry and laboratory medicineReferences. 60(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18b2c90369f9223fd09714f71c9acccd
https://pubmed.ncbi.nlm.nih.gov/35118852
https://pubmed.ncbi.nlm.nih.gov/35118852